Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
May 08, 2023 08:30 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
May 01, 2023 07:00 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
EQUITY ALERT: ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Edgio, Inc. f/k/a Limelight Networks, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – EGIO, LLNW
April 27, 2023 12:23 ET
|
The Rosen Law Firm PA
NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Edgio,...
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
April 04, 2023 17:15 ET
|
The Rosen Law Firm PA
NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom...
Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates
March 08, 2023 07:30 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023
March 01, 2023 08:30 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Access Recognized in Two Categories by Inc.’s Prestigious Inaugural Power Partner Awards
January 24, 2023 11:30 ET
|
Access Information Management Shared Services, LLC
WOBURN, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Access, the world’s largest privately-held integrated information management services provider, today announced that it has been recognized by Inc....
IO Biotech Announces Appointment of Devin Smith as General Counsel
January 23, 2023 08:00 ET
|
IO Biotech
NEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® vaccine...
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
December 28, 2022 08:00 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
MamaMancini’s Appoints Meghan Henson to Board of Directors
December 19, 2022 08:31 ET
|
MamaMancini's Holdings, Inc.
Seasoned Human Resources Executive Brings 20+ Years of Experience to the Board of Directors EAST RUTHERFORD, NJ, Dec. 19, 2022 (GLOBE NEWSWIRE) -- MamaMancini's Holdings, Inc. (NASDAQ: MMMB), a...